OptimizeRx (NASDAQ:OPRX) Issues Earnings Results

OptimizeRx (NASDAQ:OPRX) released its earnings results on Tuesday. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13, FiscalAI reports. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. The company had revenue of $19.84 million for the quarter, compared to the consensus estimate of $18.35 million.

OptimizeRx Trading Up 2.1%

Shares of NASDAQ:OPRX traded up $0.13 during mid-day trading on Tuesday, reaching $6.34. The stock had a trading volume of 597,335 shares, compared to its average volume of 436,489. The firm has a market cap of $118.94 million, a PE ratio of 24.39 and a beta of 1.19. The firm has a 50 day simple moving average of $6.61 and a two-hundred day simple moving average of $11.02. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a twelve month low of $5.54 and a twelve month high of $22.25.

OptimizeRx announced that its Board of Directors has authorized a share repurchase plan on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of OptimizeRx

A number of hedge funds have recently modified their holdings of OPRX. Manatuck Hill Partners LLC raised its position in shares of OptimizeRx by 139.5% in the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after acquiring an additional 265,000 shares during the period. Kennedy Capital Management LLC raised its position in shares of OptimizeRx by 42.8% in the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after acquiring an additional 202,446 shares during the period. Invesco Ltd. acquired a new stake in shares of OptimizeRx in the 3rd quarter valued at approximately $4,081,000. Harvest Investment Services LLC acquired a new stake in shares of OptimizeRx in the 3rd quarter valued at approximately $3,441,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of OptimizeRx in the 2nd quarter valued at approximately $2,111,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on OPRX. Stifel Nicolaus cut their target price on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Roth Mkm cut their target price on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Stephens cut their target price on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Friday, March 6th. Lake Street Capital cut their target price on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Finally, B. Riley Financial restated a “buy” rating and set a $11.00 target price (down from $28.00) on shares of OptimizeRx in a research report on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.57.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.